(rivastigmine)
Therapeutic indications: Zeyzelf® (rivastigmine) is a twice weekly transdermal patch indicated for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia.
The Zeyzelf® patch should be replaced twice weekly on fixed days (after four and three days, respectively). To optimise adherence to the skin, an oval shaped adhesive cover is provided which is applied over the active patch.
View the Prescribing Information
Adverse events should be reported
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Luye Pharma Ltd at safety@luyepharma.co.uk.
Download the Patient Leaflet here
This link will take you to the electronic medicines compendium (emc) website.
Download the SmPC
This link will take you to the electronic medicines compendium (emc) website.
Download the Educational Risk Minimisation Materials
This link will take you to the electronic medicines compendium (emc) website.
Technical information
| Active Ingredients: | Rivastigmine |
| Therapeutic area: | Neurology |
| Pharmaceutical Form: | Transdermal Patch |
Strengths, Pack size and Information
| Description | Strength | Pack Size | PIP Code |
|---|---|---|---|
| Zeyzelf® | 4.6mg | 8 patches | 5401682 |
| Zeyzelf® | 9.5mg | 8 patches | 5401674 |